Related Experiment Videos
Amikacin + ceftazidime therapy of experimental right-sided Pseudomonas aeruginosa endocarditis in rabbits
Abstract:
We investigated the efficacy of a potent new antipseudomonal beta-lactam agent, ceftazidime, in a model of right-sided Pseudomonas endocarditis in 72 rabbits. Animals received either: no therapy (controls), amikacin (15 mg/kg/day), ceftazidime (100 mg/kg/day) or amikacin + ceftazidime. Amikacin + ceftazidime was significantly more effective than single-drug regimens in terms of reduction of mortality (p less than 0.01), prevention of pulmonary infarction (p less than 0.05), reduction of mean vegetation titers of Pseudomonas aeruginosa (p less than 0.05-p less than 0.0005), sterilization of vegetations (p less than 0.0005) and reduction in prevalence of bacteriologic relapses after therapy (p less than 0.005). There was no development of resistance in vivo to either amikacin or ceftazidime.
Insights
Combination therapy with amikacin and ceftazidime significantly improved outcomes in a rabbit model of Pseudomonas endocarditis. This potent antibiotic combination effectively reduced mortality and bacterial load without inducing resistance.
Area of Science:
- Infectious Diseases
- Pharmacology
- Cardiovascular Medicine
Background:
- Pseudomonas aeruginosa is a significant cause of endocarditis, particularly in intravenous drug users.
- Right-sided endocarditis is a serious condition often associated with high morbidity and mortality.
- Effective antimicrobial therapy is crucial for managing Pseudomonas endocarditis.
Purpose of the Study:
- To evaluate the efficacy of ceftazidime, a novel antipseudomonal beta-lactam agent, in a rabbit model of right-sided Pseudomonas endocarditis.
- To compare the effectiveness of ceftazidime monotherapy and combination therapy with amikacin against Pseudomonas endocarditis.
- To assess the development of antimicrobial resistance during treatment.
Main Methods:
- A rabbit model of right-sided Pseudomonas endocarditis was established.
- Animals were randomized into four groups: no therapy, amikacin, ceftazidime, or amikacin + ceftazidime.
- Treatment efficacy was assessed by monitoring mortality, pulmonary infarction, vegetation bacterial titers, vegetation sterilization, and bacteriologic relapse rates.
Main Results:
- The combination of amikacin and ceftazidime demonstrated significantly superior efficacy compared to monotherapy.
- Combined therapy led to reduced mortality (p < 0.01) and pulmonary infarction (p < 0.05).
- Significant reductions in Pseudomonas aeruginosa vegetation titers (p < 0.05-p < 0.0005), vegetation sterilization (p < 0.0005), and bacteriologic relapses (p < 0.005) were observed with combination therapy.
Conclusions:
- Combination therapy with amikacin and ceftazidime is highly effective in treating experimental Pseudomonas endocarditis.
- This regimen offers significant advantages over single-drug approaches in reducing mortality and eradicating infection.
- No in vivo development of resistance to amikacin or ceftazidime was observed, suggesting a favorable resistance profile.